



July 21, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').

We are pleased to enclose a Press release regarding launch of Luforbec® 100/6 (beclometasone 100 µg/formoterol 6 µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease in Germany.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany

First-ever product launch in the inhalation segment in Germany

Frankfurt, Mumbai, July 21, 2023: Hormosan Pharma GmbH (Hormosan), Lupin's wholly-owned subsidiary in Germany, announced the launch of Luforbec® 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Luforbec® 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta₂-agonist (ICS/LABA) is suitable. With the same active ingredients as Foster® 100/6 pMDI and an extra fine formulation, Luforbec® offers the same licensed indications and similar device characteristics. Luforbec® pMDI provide significant cost savings, priced at - 47% below the fixed reference price on the pharmacy selling price.

With a significant portion of the population (5% of adults and 10% of children) currently undergoing asthma treatment, Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals. This launch reflects Lupin's unwavering commitment to addressing the critical needs of asthma management in Germany.

Anjan Selz, Managing Director, Hormosan Pharma GmbH, added, "The launch of Luforbec® 100/6 pMDI in Germany represents a significant milestone in our goal to establish Hormosan as a key player in the inhalation segment. We are committed to improving healthcare outcomes by ensuring the accessibility and affordability of reliable and comprehensive solutions for patients and healthcare professionals. This launch reinforces our dedication to making asthma and COPD management more accessible for the German population."

About Luforbec® 100/6 pMDI

Luforbec® 100µg/6µg is indicated in the regular treatment of asthma where the use of a combination product (inhaled corticosteroid and long-acting beta₂-agonist (ICS/LABA) is appropriate. This includes patients not adequately controlled with ICS and 'as needed' inhaled short-acting beta₂-agonist or patients already adequately controlled on both ICS and LABA.

Luforbec® 100µg/6µg is also indicated in the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

About Hormosan

Hormosan Pharma GmbH was founded in Germany more than 50 years ago and has been a part of Lupin since 2008. With innovative and generic drugs, Hormosan supports the best possible treatment in the fields of neurology, pain therapy, sexual health, and inhalation. It focuses primarily on addressing the unmet medical needs of patients, the increased inpatient benefit, and the availability of alternative therapy options.

For further information, please visit www.hormosan.de.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on -

Twitter: <https://twitter.com/LupinGlobal>

LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications and Sustainability

Email: shwetamunjal@lupin.com